Saturday, December 26, 2009

Adoptive Immunotherapy of Cancer using CD4+ T cells.Melanoma..Jim Breitfeller

Adoptive immunotherapy of cancer using CD4+ T cells
Pawel Muranski and Nicholas P Restifo

I have been in contact with Dr. Restifo and he was so generous to share his Research papers with us.

As I started to read this one, I thought it would be better to put it in the shared file on Melanoma Missionary. I think it may interest many patients.

Adoptive immunotherapy of cancer using CD4+ T cells

Hi Jim,

Thanks for the update of your analysis of the work. Have you had any luck posting this on the Wiki site? Here’s a stack of some of our recent papers. Almost all of our papers before 2008 are available on

Best regards,


Nicholas P Restifo, MD

Principal Investigator

National Cancer Institute

CD4+ T cells are central to the function of the immune system
but their role in tumor immunity remains underappreciated. It is
becoming clear that there is an enormous diversity of CD4+
T cell polarization patterns including Th1, Th2, Th17, and
regulatory T cells (Tregs). These functionally divergent T cell
subsets can have opposing effects — they can trigger tumor
rejection or inhibit treatment after adoptive cell transfer. Some
polarized CD4+ cells have plasticity, and their phenotypes and
functions can evolve in vivo. Recent advances in understanding
of polarization and differentiation of lymphocytes, as well as
some intriguing developments in the clinic, indicate that the use
of CD4+ T cell subsets in the immunotherapy of cancer has
unrealized potential.

Take care

Jimmy B

"Today might be the worst day of your life...but tomorrow could be the best. You just have to get there."

border="0" alt="For the Warriors">

Take Care,

Jimmy B

Friday, December 25, 2009

CTLA 4 Success Rate melanoma trials.. Jim Breitfeller

The most interesting data was on ipiliumumab (abstract #9033), which looked at the effect of the agent on 18 and 24 month survival from 3 phase II trials dosed at 10mg/kg every 3 weeks (plus maintenance therapy Q12W from week 24 in appropriate patients) in advanced melanoma, where survival outcomes are usually poor. Ipilumumab is a fully humanised monoclonal antibody that targets T-lymphocyte antigen 4 (CTLA-4).

The 3 studies summarised were CA184-008, CA184-022, CA184-007.

The results clearly showed that:

- 12 month survival rates were >47%
- 18 month survival rates were >34%
- 24 month survival rates were >30%

"For previously treated patients, 24 month survival rates ranged from 24% to 33%.
Long term survivors included patients with progressive disease according to WHO criteria.
These results are promising but caution must be extended because a significant number of patients were lost to follow-up, which may reduce the reliability of the results. Ongoing biomarker studies are looking at predicting which patients are most likely to benefit from ipilumumab therapy.


What did we learn from these trials? Well, there is an urgent need to define optimal endpoints for melanoma clinical trials in terms of response rate, PFS, OS and survival at 12 months. It is interesting that over the past 10 years the majority of abstracts have hyped the results in this disease as 'promising' or 'clinically active' regimens and yet very little in the way of new therapies have actually been approved by the FDA. Based on these data, I suspect it will still be a little while before we see some solid phase III data in malignant melanoma."

Take Care,

Jimmy B

Thursday, December 24, 2009

Identification and Validation of Combination Therapies for Melanomas..Jim Breitfeller

FW: Identification and Validation of Combination Therapies for Melanomas

I got my Christmas Wish!!!!!!!!!!!!!!!!!

-----Original Message-----

From: Slingluff, Craig *HS []

Sent: Thursday, December 24, 2009 11:51 AM


Cc: Weber, Michael J - Cancer Center *HS; Engelhard, Victor H

Subject: RE: Identification and Validation of Combination Therapies for Melanomas

Dear Mr. Breitfeller,

Mike Weber was kind to forward your paper and email. It appears that you have a very good sense of, and interest in, the immune response to melanoma and to cancer in general. I believe you are right that timing of the various components of the immune response, especially with combination therapies, is important, just as it is in the orchestration of a beautiful symphony. I wish you success in your treatments and in your work to understand and to explain the immune response to cancer.

Craig Slingluff

Craig L. Slingluff, Jr. M.D.

Joseph Helms Farrow Professor of Surgery

Division of Surgical Oncology

Vice-Chair for Research

Director, Human Immune Therapy Center

University of Virginia

Charlottesville, VA 22908

Melanoma and the Magic Bullet (monoclonal Antibodies)

Michael J. Weber, Ph.D.
Professor of Microbiology
Research Interests:
Signal Transducing Kinases in Cancer

Signal transduction by serine/threonine kinases
The Weber laboratory utilizes tools of cell biology, protein chemistry and molecular biology to understand how signal transduction pathways control cell growth and apoptosis and how these controls are altered in cancer. A major focus of this research is on the MAP Kinase cascade, a ubiquitous signaling pathway that generates specific biological outcomes dependent on biological context. Recent findings of the lab have demonstrated an important role for "scaffolding proteins" that assemble components of the signaling cascades. They recently discovered the MORG1 scaffold protein (MAP Kinase Organizer) that regulates responses to LPA but not EGF. Signaling scaffolds can control the location, regulation, timing, substrates, biological functions, and suitability for therapeutic intervention of a signaling pathway. This research made use of the Biostatistics Core, to help evaluate multi-factorial responses to mitogens, and the Mass Spec and DNA cores for molecular and proteomic analysis.

The lab pioneered the use of phosphorylation-site specific antibodies to probe archival paraffin-embedded pathology specimens, and discovered that the MAP Kinase cascade was activated in prostate cancer. Activation of this pathway is sufficient for and can be necessary for progression of prostate cancer to an androgen-independent disease. Therefore the Ras-MAP Kinase pathway is an attractive target for therapy of advanced prostate cancer.

Current research aims to determine how to select combinations of therapies in cancer treatment.

Merry Christmas

Jimmy Breitfeller

Take Care,

Jimmy B

Wednesday, December 23, 2009

It's Christmas.. SentoClone may be Coming to Town!!Melanoma..Jim Breitfeller

It's Christmas.. SentoClone may be Coming to Town!!!!

SentoClone AB is a Swedish biotech company developing a patented immunotherapy for cancer treatment based on autologous T lymphocytes extracted from the sentinel node, the first tumor draining lymph node. The sentinel node is resected in conjunction with tumor reducing surgery.
The extracted lymphocytes are cultivated in vitro and activated. The activated lymphocytes multiply and are given back to the patient after 4 to 6 weeks by a simple transfusion.
So far, more than 110 patients have been treated. As the therapy is based on autologous cells, significant side effects are not expected and have not been seen.
A randomised controlled phase II study in advanced malignant melanoma has recently been started and further studies are planned in other indications.

Merry Christmas!!!!!!

Jimmy B

Today might be the worst day of your life...but tomorrow could be the best. You just have to get there."

For the Warriors

Tuesday, December 22, 2009

Bristol-Meyer Squibb the New Dr. Kevorkian of the Decade?Melanoma..Jim Breitfeller

Is Bristol-Meyer Squibb the New Dr. Kevorkian of the Decade?

• Mislead the public/Government about the Ipilimumab Shortage
• Stopped the compassionate drug use on 9/12/2008
• Continued to create/open clinical trials with Ipilimumab
• Increased their stock dividend as of February 2010
• Continuously turn away Melanoma patients that did not qualify for their trials

As a Melanoma Patient and a survivor, I believe BMS is the New Dr. Kevorkian.
They are killing cancer patients that have no other alternative and Anti-CTLA-4 blockage was their last hope.
“Scientists have discovered that an important mechanism for down regulation is mediated by a molecule called CTLA-4. The T cells are initially activated by other immune cells, called dendritic cells, that display the foreign, or cancerous, antigens to the T cells and instruct them to be active. After this initial activation, CTLA-4 appears on the surface of the T cells, and when CTLA-4 interacts with the dendritic cells, the next set of signals are to turn the response down, or even off. CTLA-4 is part of a regulatory mechanism that normally protects the body from immune overreactions, but when it is expressed in the presence of mutant cancer cells the result is tumor evasion of the immune response. Ipilimumab is an antibody that blocks CTLA-4, releasing this safety brake, and allowing the immune response to have a stronger anti-tumor effect.”

Source: Oregon Health and Science University

With Bristol-Meyer Squibb not allowing compassionate drug use, they are invoking a death sentence on the cancer patient. Since Pfizer pulled out of this therapy due to the fact they wanted the drug as a monotherapy when the scientific data suggests that a combination of this drug would have better results. So BMS now has a monopoly on this drug and will be able to charge a great deal for it even though it is made in thousands of units per batch. When will the FDA coming in and do what is ethical for the country?

We cannot let a deceitful and greedy company control our destiny.

“In our daily life, we encounter people/companies who are deceitful, intent only on satisfying their own needs. There is so much anger, distrust, greed, and pettiness that we are losing our capacity to work well together to do what is ethically right.”
Jimmy B

Take Care,

Jimmy B

Sunday, December 20, 2009

Bristol Meyer Squibb."When you marry the devil's daughter don't be surprised when your father-in-law comes to visit."Melanoma.. jim breitfeller

Mead Johnson Loses $13.5 Million Lawsuit to PBM Products

December 2, 2009 11:23 AM EST

PBM Products, LLC, has received a favorable jury verdict and a $13.5 million damages award in its false advertising lawsuit against Mead Johnson & Co., the operating subsidiary of Mead Johnson Nutrition Company (NYSE: MJN), the makers of the national-brand Enfamil(R) LIPIL(R) Infant Formula. Mead Johnson is 83 percent-owned by Bristol-Myers Squibb (NYSE: BMY).

PBM's lawsuit claimed that Mead Johnson engaged in false and misleading campaigns against PBM's competing store-brand of infant formulas, suggesting they do not provide the same nutrition as Mead Johnson's brands. PBM's store-brand infant formulas cost up to 50 percent less than Enfamil(R) LIPIL(R). The $13.5 million in damages awarded by the jury in the United States District Court for the Eastern District of Virginia is one of the largest damages awards ever for a false advertising case.

(Source PBM Products)

If BMS is willing to mislead on baby formula, Can you believe that they was ever a Ipilimumab Shortage?

All smoke and mirrors!!!!!!!

I see a pattern of misleading the public over the last decade from Bristol-Meyer Squibb.

Take Care,

Jimmy B

Saturday, December 19, 2009

Patient’s own infection-fighting T cells put late-stage melanoma into long-term remission..Melanoma Jim Breitfeller

Patient’s own infection-fighting T cells put late-stage melanoma into long-term remission

Researchers identify the first successful end of a human patient’s cloned infection-fighting T cells as the sole psychotherapy to snap an advanced through-and-through-tumor cancer into long-term exemption. A body led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.

Yee and colleagues removed CD4+ T cells, a type of white blood cell, from a 52-year-old man whose Stage 4 melanoma had spread to a groin lymph node and to a lung. T cells specific to targeting the melanoma were then expanded vastly in the laboratory using modifications to existing methods. The lab-grown cells were then infused into the patient with no additional pre- or post-conditioning therapies, such as growth-factor or cytokine treatment. Two months later, PET and CT scans revealed no tumors. The patient remained disease free two years later, when he was last checked.

“We were surprised by the anti-tumor effect of these CD4 T cells and its duration of response,” Yee said. “For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study.”

Yee cautioned that these results, presented in the journal’s “Brief Report” section, represent only one patient with a specific type of immune system whose tumor cells expressed a specific antigen. More studies are needed to confirm the effectiveness of the experimental T-cell therapy. If proven successful in more patients, Yee predicted this therapy could be used for the 25 percent of all late-stage melanoma patients who have the same immune-system type and tumor antigen.

Using a patient’s own immune system to combat cancer, called immunotherapy, is a growing area of research that aims to develop less-toxic cancer treatments than standard chemotherapy and radiation.

The patient in the journal report was one of nine patients with metastatic melanoma who were being treated in a recently completed clinical trial to test dose- escalation of autologous CD4+ T cells. Earlier studies performed by Yee used CD8+ T cells, which do not persist in the body without the support of CD4+ T cells or growth factors such as interleukin 2. Yee and colleagues theorized that infusion of a massive dose of CD4+ T cells would persist longer in the body because they make their own growth factor, interleukin 2, while stimulating the anti-tumor effect of the patient’s existing CD8+ T cells. However, until recently there was no feasible way to isolate and expand anti-tumor CD4+ T cells in the lab.

The researchers were successful in all of these areas. The patient received a dose of 5 billion cloned CD4+ T cells with specificity for the melanoma-associated NY-ESO-1 antigen. The cells persisted for at least 80 days in the patient’s body. And, even though only 50 percent to 75 percent of the patient’s tumor cells expressed the NY-ESO-1 antigen, the entire tumor regressed following the infusion. The scientists postulated that the patient’s immune response was broadened to other antigens expressed by the tumor cells. Follow-up tests showed T-cell responses to two additional tumor antigens, MAGE-3 and MART-1.

Researchers in Yee’s lab, the University of Washington School of Medicine and the Ludwig Institute for Cancer Research in New York collaborated on the research. The Burroughs-Wellcome Foundation, Damon Runyon Cancer Research Foundation, Edson Foundation and National Cancer Institute funded the study.

This was written by collegeseattle

"Today might be the worst day of your life...but tomorrow could be the best. You just have to get there."

For the Warriors

Take Care,

Jimmy B

Thursday, December 17, 2009

Bristol-Meyer Squibb.."When you marry the devil's daughter don't be surprised when your father-in-law comes to visit."Melanoma.. Jim Breitfeller

Monday, May 18, 2009
Quote of the week - and It's only Monday morning!

"When you marry the devil's daughter don't be surprised when your father-in-law comes to visit."

Corey Nahman writes:

A Celebrity Patient's Backing Turns Sour for Drug Company … wasn't the truth, he says now. Within weeks of taking Abilify, Mr. Behrman says he felt stiffness and agitation in his legs. He says Abilify clouded his thinking. He now says the drug made him feel worse than any treatment he has tried…[Wall Street Journal]

Editor's Note: Sequence of events: (A) Bristol hires author/bipolar patient to tell the world how great Abilify is, pays him $10K per day in speaking fees and he tells everyone it is the best thing since sliced bread.(B) His contract is over and he demands $7.5 million to renew; BMS tells him to shove it.(C) Now he's going around saying that he lied all along and Abilify hade him feel like crap.

Bottom Line: When you marry the devil's daughter don't be surprised when your father-in-law comes to visit.

This happened in 2009. BMS still has not changes it's way of doing business. It is all about the bottom-line and how to make a profit.

Now think about the Ipilimumab Shortage. Go to the Clininal Trial website and see all the trials started after the shortage/ stoppage of the the compassionate drug use (Ipilimumab).

This is not rocket science

We been had!!!!

Patients have died due to the fact they did not have access to Ipilimumab.

BMS only cares about the bottom-line. What about what is ethically right?

They are the Tiger Woods of the pharma companies.We should boycott them.


Take Care,

Jimmy B

Monday, December 14, 2009

2009 Sustainability Reporting of the World's Largest Pharmaceutical Companies (BMS)..What about Ethics??? Melanoma ..Jim Breitfeller

Dr. Morhardt,

While reading the Scores

2009 Sustainability Reporting of the World's Largest

Pharmaceutical Companies

A benchmarking tool for online sustainability reporting

Roberts Environmental Center


I have some comments:

While base on your environmental standards Bristol-Meyers Squibb is worthy of an A+, their Ethical conduct should be also taken into account. As a patient of stage IV Melanoma Cancer, I saw firsthand what BMS is all about. It is greed and the bottom line and the “string of Pearls”. They chose to close the compassionate drug use (Ipilimumab). They told the public and the Government that they were having trouble producing the drug, but proceeded to startup new Clinical trials with the drug after they stopped compassionate drug use. How ethical is that? They even went as far to respond to a patient’s family with this response;” Jimmy, remember what the BMS "doctor" told me "Mrs. Lawrence, you will get the drug for your husband when we can charge for it."

BMS is only looking out for their bottom-line and to hell with patients.

So with this information, BMS in my opinion is only worth a C- to a D+, not an A+.

You can’t just use what they say on their website. You need to do real research. The information on their website is skewed in the drug companies favor.

Best regards,

Jim Breitfeller Patient/Survivor/Researcher of Stage IV Melanoma

Take Care,

Jimmy B

Tuesday, December 8, 2009

In this Holiday Season there is a Scrooge (Bristol Meyer Squibb) among us!! Melanoma..Jim Breitfeller

In this Holiday Season there is a Scrooge among us. It is the Bristol-Meyer Squibb. In September of 2008 they stopped compassionate drug use (Ipilimumab) because they claimed that they were having trouble producing it. It has come to light that their major intension was to stop giving it away until they could get paid for it. The Shortage was a Magic act. Now it’s there and now it’s not.

To make matters worse, The FDA was contacted and never really looked into the Shortage. Did they turn blind eye or are they short staffed?

I have reason to believe Bristol-Meyer Squibb is the poster boy for Scrooge this Holiday Season In their Company Documents they say:

“What sets us apart? We believe it's our commitment to patients with serious diseases, our focus on finding innovative medicines that combat those diseases, and our dedication to extending and enhancing human life.”
Bristol-Meyer Squibb is committed to their bottom line. They are the Scrooge of the pharmaceutical Industry in my opinion. They all do it, just not as publicly as Bristol-Meyer Squibb.

The company should be investigated on their ethics.

1. They mislead Government officials, the truth about the shortage?
2. They added new Clinical Trials after they stopped Compassionate Drug Use
3. They mislead the general public (The Melanoma Patients)
4. They went so far to amend their Compassionate use protocol to read “the study will be closed to enrollment upon market availability and then need to switch to commercial supply.”

5. Jimmy, remember what the BMS "doctor" told me "Mrs., you will get the drug for your husband when we can charge for it."

This all comes down to Ethics. Doing what is right.

I say to Bristol-Meyer Squibb

“BAH HUM BUG!!!!!”


Please sign the E-Petition at Melanoma Missionary
Your Life may depend on it

Take Care,

Jimmy B

Friday, December 4, 2009

GM-CSF-based Second-generation Oncolytic Herpesvirus Vaccine Promising for Melanoma..Jim Breitfeller

GM-CSF-based Second-generation Oncolytic Herpesvirus Vaccine Promising for Melanoma

Researchers involved in an international multicenter clinical Phase II trial have reported a 26% response rate for patients with metastatic melanoma treated with a second-generation granulocyte-macrophage colony-stimulating factor (GM-CSF) oncolytic herpes simplex virus (HSV) vaccine. The details of this study were published in the December 1, 2009 issue of the Journal of Clinical Oncology.[1]

Melanoma is considered an immune responsive cancer. A small fraction of patients with metastatic disease respond to a variety of immune therapies including: Proleukin® (interleukin-2), lymphokine activated killer (LAK) cells, tumor infiltrating lymphocytes (TIL), and genetically manipulated T-cells. In addition, there have been many attempts to develop a successful vaccine.

A previous Phase I study of this second-generation oncolytic HSV expressing GM-CSF was carried out in patients with a variety of solid tumors. In this study the vaccine was called OncoVEX-GM-CSF and is made by BioVex.[2] This study established a safe dose, and responses were observed in patients with melanoma and other solid tumors.

The current study evaluated the same vaccine, which is called JS1/34.5/47-/GM-CSF, for the treatment of 50 patients with metastatic melanoma. Seventy-five percent of patients in this study had failed one or more systemic therapies. Vaccine was injected into tumor nodules every two weeks for up to 24 treatments, and some patients who responded or were stable were then treated on an extended protocol. These authors made the following observations:

The overall response rate was 26%.
Eight patients (16%) had a complete response.
Five patients (10%) had a partial response.
Responses occurred in injected and distant sites.
10 patients (20%) had stable disease for more than three months.
92% of responses were maintained for 7-31 months.
Two additional patients had a complete response after surgery.
Two additional patients with an initial partial response or stable disease achieved a complete response after 24 months of further vaccination.
Overall survival at one year was 58% and 52% at two years.
Comments: These are the best results achieved to date for any vaccine for melanoma. This study will by followed up by a Phase III study to confirm these results.



[1] Senzer JJ, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. Journal of Clinical Oncology. 2009;27:5763-5771.

[2] Hu JC, Coffin RS, Davis CJ, et al: A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 12:6737–6747, 2006.


Take Care,

Jimmy B

Greetings to One and All

This Blog is dedicated My Brother Kenny B. who passed away in the late 1970's with Cancer before the Internet.

It was he, who showed me How to live and give back. He was wise beyond his years.

Kenny B

Jimmy and Dee

Carepage: Jimmybreitfeller
Jimmy Breitfeller

My Profile as of 2009

My photo
Last July (2005)I was riding my bicycle to work at the Eastman Kodak Research Labs about 3 miles from home. I was wearing a knapsack to carry my things to and from the labs. I started noticing an ache on my back. So I decide to go to the dermatologist. To make the long story short, it was cancer. I knew from my research that I would be needing adjuvant therapy. So I started communicating with Sloan Kettering, University of Pittsburgh Cancer Center, and a couple of others including the Wilmot Cancer Center at Strong. I realized that by telling my story, I might help someone else out there in a similar situation. So to all who are linked by diagnosis or by relation to someone with melanoma, I wish you well. Stay positive, read as much as you can (information helps to eliminate the fear associated with the unknown), and live for today, as no one can predict what tomorrow may bring. Jimmy B. posted 12/15/08


The information contained within this Blog is not meant to replace the examination or advice of your Oncologist or Medical Team. The educational material that is covered here or Linked to, does not cover every detail of each disorder discussed.

Only your physician/Oncologist can make medical decisions and treatment plans that are appropriate for you. But, An Educated Consumer is a Smart consumer.

As Dr. Casey Culberson Said:

"The BEST melanoma patient is an ACTIVE PARTICIPANT in his or her treatment

Melanoma and the “Magic Bullet” (Monoclonal Antibodies)

Just to let you know I posted the first draft of the Melanoma and the “Magic Bullet” (Monoclonal Antibodies). on Melanoma Missionary In the Shared File Section. you can download it for 19.95 (Only kidding) it is Free for the taking.

It is 33 pages long and may help you in your quest for the Yellow Brick Broad. Just to let you know it is only the first draft. Revisions are sure to come. I wanted to get it to the people that need it the most, the Melanoma Patients.


So, where does Interluekin-2 (IL-2) come into play? According to Byung-Scok et al and recent reports, IL-2 is not needed for developmental CD4+ CD25+ Treg cells in the thymus but does play an important role in the maintenance and function in the peripheral.18 Peripheral is defines as secondary system outside the bone marrow and thymus. It entails the site of antigen, immune system interaction. IL-2 is required for the peripheral generation of Tregs based Abbas’s and colleagues research.19

IL-2 prevents the spontaneous apoptosis of the CD4+ CD25+ Treg cells. It has been reported that patients with multiple advance-stage tumors have elevated levels of Tregs within the tumor microenviroment.20 Interluekin-2 is the survival factor for CD4+ CD25+ Treg cells.21 If the addition of IL-2 is on or before the maximum propagation of the CD4+ T cells, the Tregs population can increase 5-fold in a 96 hour period based on certain growth mediums.

By controlling the addition of the endogenous IL-2, one has a knob to turn and can lead to the control of the expansion of the Tregs. When you combined this control with the anti-CTLA-4 blockage, you can shift the balance of the immune response.

Now here is the catch. The maintenance and function of the CD8+ T-cells require CD4+ cells which secrete IL-2. So we don’t want to deplete the CD4+ cells, we want to control the expansion of the Tregs which are a subset of the CD4+ cells. It has been postulated by some researchers that the Anti-CTLA-4 blockage also suppresses the Treg function in a different mechanism. By using IL-2 as the rate limiting factor, we can suppress the CD4+ CD25+ Treg cell expansion by controlling the concentration and timing of the Inerluekin-2 at the tumor microenvironment.

The Interluekin-2 plays another role in this Melanoma Maze. In a study by Janas et al, Il-2 increases the expressions of the perforin and granzyme A, B and C genes in the CD8+ T-cells. This increase expression causes the CD8+ T-cells to mature into Cytoxic T Lymphocytes (CTLs). The exogenous IL-2 is required for the granzyme proteins. As stated previously, CTLs have cytoplasmic granules that contain the proteins perforin and granzymes. A dozen or more perforin molecules insert themselves into the plasma membrane of target cells forming a pore that enables granzymes to enter the cell. Once in the tumor cell, these enzymes are able to breakup (lyse) the cell and destroy it. This is the beginning of the end for the cancer cells. The tumors begin to shrink and the rest is history,

On the other hand, prolong therapy with Il-2 can result in causing apoptotic death of the tumor- specific CD8+ T-cells.23

Clearly in a clinical setting, timing, dose, and exposure to these drugs play a major roll in the immunotherapy, and can have dramatic effects on the outcome.

All it takes is that one magic bullet to start the immune reaction..

Melanoma And The Magic Bullet (Monoclonal Antibodies)

Public Service Announcement

A call for Melanoma Patients by Dr. Steven A Rosenberg

"We continue to see a high rate of clinical responses in our cell transfer immunotherapy treatments for patients with metastatic melanoma", Dr. Rosenberg said.

"We are actively seeking patients for these trials and any note of that on a patient-directed web site would be appreciated."

If you would like to apply for his trials, here is the website and information.

Dr. Rosenberg's information

Dr. Rosenberg's Clinical Trials

For the Warriors

The Melanoma Research Alliance has partnered with Bruce Springsteen, the E Street Band, and the Federici family to alleviate suffering and death from melanoma. Please view Bruce Springsteen’s public service announcement inspired by Danny Federici. Danny was the E Street Band’s organist and keyboard player. He died on April 17, 2008 at Memorial Sloan-Kettering Cancer Center in New York City after a three year battle with melanoma.

Source Fastcures blog

Join the Relay for Life!!!


Dear Family and Friends,

I’ve decided to take a stand and fight back against cancer by participating in the American Cancer Society Relay For Life® event right here in my community! Please support me in this important cause by making a secure, tax-deductible donation online using the link below.

To donate on line now, click here to visit my personal page.
Jimmy B AKA Melanoma_Missionary

Relay For Life® is a life-changing event that brings together more than 3.5 million people worldwide to:

CELEBRATE the lives of those who have battled cancer. The strength of survivors inspires others to continue to fight.

REMEMBER loved ones lost to the disease. At Relay, people who have walked alongside people battling cancer can grieve and find healing.

FIGHT BACK. We Relay because we have been touched by cancer and desperately want to put an end to the disease.

Whatever you can give will help - it all adds up! I greatly appreciate your support and will keep you posted on my progress.

Keep the Fire Burning!!!



Jimmy Breitfeller
Turn off Music before you "Click to Play"
Signs of Melanoma Carcinoma Skin Cancer

How Skin Cancer Develops by " : Dermatology"

Call for Patients with Unresectable Liver Metastases Due to Melanoma

Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma

Delcath is actively enrolling patients in a Phase III clinical trial testing its proprietary drug delivery system, known as Percutaneous Hepatic Perfusion (“PHP”), with melphalan for the treatment of ocular and cutaneous melanoma metastatic to the liver.

This NCI-led trial is enrolling patients at leading cancer centers throughout the United States. Commenting on these orphan-drug designations, Richard L. Taney, President and CEO of Delcath, stated, “These favorable designations are important steps in our efforts to secure Delcath’s commercial position upon conclusion of our pivotal Phase III trial for metastatic melanoma. We remain steadfast in our commitment to become the leader in the regional treatment of liver cancers and we continue to enroll patients in this study, and advance our technology and the promise that it offers to patients with these deadly forms of melanoma and other cancers of the liver, all with limited treatment options.”

Orphan drug designation, when granted by the FDA’s Office of Orphan Products Development, allows for up to seven years of market exclusivity upon FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.

Current Trial Centers

Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using
Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies

James F. Pingpank, Jr., MD, FACS
Associate Professor of Surgery
Division of Surgical Oncology
Suite 406, UPMC Cancer Pavillion
5150 Centre Avenue
Pittsburgh, PA 15232
412-692-2852 (Office)
412-692-2520 (Fax)

Blog Archive

Call For Melanoma Patients!!!!

Call For Melanoma Patients!!!!

Dr. Rosenberg Has a New Clinical Trial.

Our latest treatment has a 72% objective response rate with 36% complete responses.

We are currently recruiting patients for our latest trial.

Is there some way to post this “Call for Patients” on the web site?

Steve Rosenberg

Dr. Rosenberg's Clinical Trials

(For a copy of the research paper.. see My Shared files)

The news headlines shown above for Melanoma / Skin Cancer are provided courtesy of Medical News Today.